van Breukelen F J, Mattson K, Giaccone G, van Zandwijk N, Planteydt H T, Kirkpatrick A, Dalesio O
Spaarne Ziekenhuis, Haarlem, The Netherlands.
Eur J Cancer. 1991;27(12):1627-9. doi: 10.1016/0277-5379(91)90430-l.
46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.
46例恶性胸膜间皮瘤患者进入一项米托蒽醌每3周14mg/m²的II期研究。组织学由病理专家小组确认。所有患者此前均未接受过化疗。毒性主要为轻度胃肠道和血液学副作用。在34例评估疗效的患者中，仅记录到1例部分缓解。该剂量和给药方案的米托蒽醌在恶性间皮瘤中的活性有限。
